Japan’s Central Social Insurance Medical Council (Chuikyo) on October 15 approved the reimbursement listing of five new medicines, with the…
ACADEMIA
Japan Pediatric Society Recommends COVID Jab for Ages 4 Years and Younger
Japanese groups of medical experts, including the Japan Pediatric Society (JPS), announced on November 2 that they recommend COVID-19 vaccinations for children at ages six months to 4 years, regardless of underlying health conditions. The decision was made as experts…
To read the full story
ACADEMIA
- Japan Sleep Society to Revise Insomnia Guidelines to Reflect Orexin Antagonists
October 8, 2025
- Japan’s Sakaguchi Wins 2025 Nobel Prize in Medicine
October 7, 2025
- Japanese Medical Societies Strongly Recommend COVID Vaccinations from October
September 3, 2025
- Cardiologist Sees Promise in Airwin as First PAH Med to Tackle Disease Progression
September 3, 2025
- Tohoku University Trial Finds Kidney Benefits for Constipation Drug Lubiprostone
September 3, 2025
Members of the Central Social Insurance Medical Council (Chuikyo) broadly agreed on October 17 that incentives under the medical fee…
With biosimilars of Eylea (aflibercept) expected to reach the Japanese market in November, all eyes are on whether the originator’s…
In the dynamic pharmaceutical landscape, especially within the nuanced Japanese market, leadership hinges on acute awareness. This transcends surface-level observations, demanding a deep understanding of regulatory shifts, cultural sensitivities, and evolving patient needs. For leaders in this sector, particularly those…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…